Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds At AACR Meeting
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage, precision-oncology biopharmaceutical company, shared new data today from the company's preclinical synthetic lethality program. The findings, which are now